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Background: Transcription factor overexpression is common in biological experiments and transcription factor
amplification is associated with many cancers, yet few studies have directly compared the DNA-binding profiles of
endogenous versus overexpressed transcription factors.
Methods: We analyzed MyoD ChIP-seq data from C2C12 mouse myotubes, primary mouse myotubes, and mouse
fibroblasts differentiated into muscle cells by overexpression of MyoD and compared the genome-wide binding
profiles and binding site characteristics of endogenous and overexpressed MyoD.
Results: Overexpressed MyoD bound to the same sites occupied by endogenous MyoD and possessed the same
E-box sequence preference and co-factor site enrichments, and did not bind to new sites with distinct characteristics.
Conclusions: Our data demonstrate a robust fidelity of transcription factor binding sites over a range of expression
levels and that increased amounts of transcription factor increase the binding at physiologically bound sites.
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The biological sciences have always relied on model sys-
tems to test specific hypotheses, and the general validity of
each model system is constantly subject to vigorous debate.
This is particularly true when transcription factors are
overexpressed in cells, and the investigator(s) extrapolate
their findings to the function of the endogenous factor. Al-
though overexpression studies have yielded many signifi-
cant advances in our understanding of cell biology, their
validity is routinely challenged, particularly in manuscript
and grant reviews. Intuitively this skepticism is justified.
Biochemistry predicts that higher factor concentrations will
drive non-physiological protein interactions or, in the case
of transcription factors, DNA binding. Therefore, it is often
asserted that overexpression of a transcription factor will
not accurately reflect the function of that factor at physio-
logic levels of expression or, at a minimum, that there is no* Correspondence: stapscot@fhcrc.org
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reproduction in any medium, provided the orbasis to assume that it does. As logical as this assertion
may seem, there is very little experimental evidence to sup-
port or refute it, possibly because genome-wide factor
binding and transcriptional activation have only recently
been possible to assess. Yet, understanding the functional
consequences of transcription factor overexpression is very
important in cancer cell biology where gene amplifications,
such as N-MYC amplification in neuroblastomas, promote
tumor progression.
Previously we reported the genome-wide binding of en-
dogenous MyoD in mouse muscle cells and compared
that to exogenously expressed MyoD in mouse embryonic
fibroblasts (MEFs) transduced with a MyoD expressing
retrovirus [1]. The transduced MEFs had levels of MyoD
protein very similar to the endogenous MyoD and showed
a very similar binding profile. Here we compare the
genome-wide binding of endogenous MyoD in mouse
skeletal muscle cells with highly overexpressed MyoD in
MEFs to determine whether overexpression qualitatively
alters the binding profile. We find that the overexpressed
MyoD binds to the same sites as endogenous MyoD and
does not demonstrate binding to novel regions or motifs.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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identifies sites bound by endogenous MyoD, suggesting an
intrinsic biological robustness for varying levels of tran-
scription factor in a cell.
Methods
ChIP-seq
ChIP was performed as previously described [1,2]. ChIP
samples were prepared for sequencing per the Illumina
Sample Preparation protocol with two modifications: (1)
DNA fragments of 150–300 bp were selected at the gel-
selection step; (2) 21 cycles of PCR were performed at
the amplification step instead of 18. For the control sam-
ples, untransduced MEFs derived from Myod−/−/Myf5−/−
mice were ChIPed with MYOD antibody, and mouse
myotubes were ChIPed with preimmune serum.
MyoD lentivirus
cDNA for Myod was cloned into the GFP locus of
the pRRL.SIN.cPPT.PGK-GFP.WPRE lentiviral backbone
(Addgene), with expression thus driven by the Pgk pro-
moter. Replication-incompetent lentiviral particles were
packaged in 293T cells by the Fred Hutchinson Cancer
Research Center Lentivirus Core Facility. MEFs were
transduced in DMEM containing polybrene at 8 μg /ml.
After 24 h, media were replaced; cells were switched to
differentiation media (1% heat inactivated horse serum,
10 μg/ml insulin, 10 μg/ml transferrin) 48 h after
infection and harvested 36–40 h later. ChIP and Western
blot were performed with a previously characterized
MYOD antibody [3]. Western blot bands were quantified
with ImageJ.
ChIP-seq peak calling and significance inference
Sequences were extracted using the GApipeline soft-
ware. Reads mapping to the X and Y chromosomes were
excluded from our analysis. Reads were aligned using
MAQ to the mouse genome (mm9). Duplicate se-
quences were discarded to minimize effects of PCR
amplification. Each read was extended in the sequencing
orientation to a total of 200 bases to infer the coverage
at each genomic position. Peak calling was performed by
an in-house developed R package that models back-
ground reads by a negative binomial distribution condi-
tioned on GC content as previously described [1,2,4].
The control ChIP-seq sample was used to eliminate sta-
tistically significant peaks likely due to artifact.
Motif analysis
We used a discriminative de-novo motif discovery tool de-
scribed previously [2] to find motifs that distinguish fore-
ground and background sequence data sets. To find
motifs enriched under ChIP-seq peaks, we selected back-
ground sequences using random genomic regions sampledwith similar GC content and distance to TSS. We infer a
positional weight matrix (PWM) model from an output
motif using an iterative expectation-maximization (EM)
refinement process, which is similar to MEME [5].
ChIP-seq sample comparison
The scatter plot of the MyoD peak heights in the two
samples (endogenous MyoD and lenti-MyoD) indicated
a strong correlation (Pearson correlation 0.52 with asinh
transformation). Nevertheless, due to the different ori-
gins of samples, the overall variation between the two
was still far greater than their respective technical repli-
cates (data not shown). Therefore, it was challenging to
apply an appropriate statistical null model to capture the
stochastic variation between the two systems and to
identify exactly the set of peaks that are identical or dif-
ferent between the samples. Therefore, we chose a non-
parametric approach by comparing the overlap of peaks
at a spectrum of different rank cutoffs in order to out-
line the global landscape of peak similarity. Cross cell-
type comparison was performed similarly as previously
described [4]. We ranked all peaks by their p-values and
group ranks into bins of 5,000 (i.e., the top 5K peaks,
then the top 10K peaks, etc.). Then we computed the
fraction of the top x peaks in one sample that overlap
with the top y peaks in another sample, where x and y
vary from 5K to 110K, and y is equal to or greater than x.
To compare the coverage at E-boxes in endogenous and
lenti peaks, and to quantify the distribution of peak height
ratios between the two samples, we adjusted for the differ-
ent numbers of total reads by sub-sampling equal num-
bers of endogenous and lenti reads and recomputed the
coverage and peak height at these sites.
Ethical approval
This study did not directly use vertebrate animals or hu-
man subjects and did not require ethical approval.
Results
Comparison of different MyoD expression levels in the
conversion of fibroblasts to skeletal muscle
Mouse embryonic fibroblasts (MEFs) can be converted to
skeletal muscle by the forced expression of MyoD. To de-
termine whether overexpression of MyoD can reliably
identify biologically relevant binding sites, we compared
the binding profile of the endogenous MyoD in mouse
muscle cells to the MyoD binding profile in MEFs with
exogenously overexpressed MyoD. Transduction of MEFs
with a lentivirus expressing MyoD from the Pgk promoter
(lenti-MyoD) induced differentiation to skeletal muscle as
determined by fusion and expression of myosin heavy
chain (Figure 1A). Western analysis demonstrated that
lenti-MyoD cells had approximately four-fold higher levels
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myotubes (Figure 1B).
Overexpressed MyoD binds the same sites as
endogenous MyoD
To determine whether overexpressed MyoD can accur-
ately identify sites bound by endogenous MyoD, we
compared a ChIP-seq data set obtained from MEFs
transduced with lenti-MyoD [4] to our previous ChIP-
seq data from endogenous MyoD in mouse myotubes
[1]. The lenti-MyoD data set had 17.5 million mapped
unique reads, and we combined endogenous MyoD
ChIP-seq data from mouse C2C12 myotubes (6.5 million
reads) and primary differentiated cultured mouse muscle
cells (8.5 million reads) to achieve a comparable total 15
million reads for endogenous MyoD because our prior
analysis [1] demonstrated a high concordance of peak lo-
cations between these two samples. These reads were
processed and peaks were identified as described in
Methods and Additional file 1: Figure S1A and B. The
control ChIP-seq samples (~18 million pooled reads from
pre-immune ChIP in muscle cells, MyoD antisera ChIP in
MEFs that do not express MyoD, and beads alone)
contained a small number of high peaks (Additional file 1:
Figure S1B), which were found at similar locations in allFigure 1 MEFs transduced with MyoD lentivirus. (A) MEFs
transduced with MyoD lentivirus demonstrate nearly complete
conversion into myotubes 72 h after infection (red: MYOD antibody;
green: myosin heavy chain antibody; blue: DAPI). (B) Western blot
demonstrates higher MyoD expression in MEFs transduced with
MyoD lentivirus (2) compared to control MEFs (1), C2C12 myoblasts
(3), and C2C12 myotubes (4). Tubulin blot demonstrates
equivalent loading.three control ChIP samples (data not shown) and remain
of unknown etiology. These non-MyoD peaks were
subtracted from the MyoD ChIP-seq data sets.
ChIP-seq for the endogenous MyoD identified ~37,000
peaks at a p-value (see Methods) of 10-10 (read cutoff
~20), ~67,000 peaks at a p-value of 10-5 (read cutoff
~11), and ~117,000 at a p-value of 10-3 (read cutoff ~8).
A similar range of peaks was identified by the overexpressed
MyoD but at slightly higher p-value thresholds: ~35,000
(p~10-20, cutoff ~50), ~68,000 (p~10-10, cutoff ~26), and
~122,000 (p~10-5, cutoff ~14). At a given p-value, the
overexpressed MyoD had approximately twice the number
of peaks compared to the endogenous MyoD. This could ei-
ther represent higher occupancy of the same sites bound by
the endogenous MyoD or a large number of off-target sites
bound by the overexpressed MyoD and not bound by the
endogenous MyoD.
To accurately compare the similarity, or overlap, of
MyoD binding sites in the different samples, we used a
non-parametric approach that compared the overlap of
peak locations based on the rank order of the peaks in
each sample (see Methods). Comparing the top 35,000
peaks bound by endogenous MyoD and lenti-MyoD,
there was a 67% overlap, and the overlap was similar
comparing the top 70,000 or 110,000 peaks for each
(Figure 2A). The lack of a complete overlap at each cut-
off was largely due to the rank-order of the peaks (based
on p-value) rather than distinct binding regions, because
87% of the top 35,000 lenti-MyoD peaks were repre-
sented in the top 70,000 endogenous-MyoD peaks and
93% in the top 110,000 endogenous-MyoD peaks.
Similarly, 85% and 91% of the top 35,000 endogenous-
MyoD peaks were present in the top 70,000 and 110,000
lenti-MyoD peaks, respectively. A more detailed represen-
tation of this data is shown in Figure 2B. Therefore,
although there were some differences in the rank order of
the peaks, the locations were almost the same with greater
than 90% concordance.
Overexpressed MyoD binds the same motifs as
endogenous MyoD
Since MyoD binds as a heterodimer with an E-protein to
an E-box containing a CANNTG core sequence, with
preference for GC or CC as the internal nucleotides
[1,4], we next determined whether overexpression of
MyoD resulted in binding to a distinct set of low affinity
sites or sites that might reflect homodimers or other
protein complexes. We used two different approaches to
determine the binding site preferences for endogenous
and overexpressed MyoD.
First, we ranked all of the approximately 15 million E-boxes
in the mouse genome based on their ChIP-seq coverage
(see Methods for details of the statistical model) and then
binned them by rank as the top 1,000, 1,001–10,000,
Figure 2 The MyoD binding regions are largely shared between overexpressed MyoD in MEFs and endogenous MyoD. (A) Overlap of
lenti-MyoD peaks with endogenous MyoD peaks. To assess the concordance between the two samples, we selected the top 5K to 110K
peaks in each sample based on p-value. We calculated the number of overlapping peaks for the top peak sets at various rank cutoffs
in both samples and divided this number by the size of the smaller peak set. Specifically, for a cell corresponding to the top x peaks
in sample 1 compared to the top y peaks in sample 2, the fraction is computed as the number of overlapping peaks divided by the
smaller value of x or y. (B) The overlapping fractions were calculated as in A and are plotted with color-coding as specified in the figure.
For example, in the cell at the row labeled 5K and column labeled 10K, we plotted the fraction of the top 5K peaks in lenti-MyoD that
overlap with the top 10K peaks in primary + C2C12 myotubes.
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the CAGCTG and CACCTG E-boxes were enriched for
MyoD binding (Figure 3A) in similar proportions within
each bin. Therefore, overexpressed MyoD binds a similar
distribution of E-box sequences as the endogenous MyoD.
For the second approach to determine whether
overexpression of MyoD resulted in binding to a different
set of E-boxes, we used a motif discovery algorithm to
identify preferred E-box sequences associated with the top
35,000 ranked peaks (ranked on p-value), the 35,001-
70,000 peaks, and the 70,001-110,000 peaks for bothendogenous MyoD and overexpressed MyoD (Figure 3B).
The identified E-box motifs, and flanking preferences
were nearly identical for endogenous MyoD and
overexpressed MyoD at different rankings, although
the lower ranked peaks had a slightly more degener-
ate sequence compared to the higher ranked peaks in
both groups. Plotting the average position weight
matrix (PWM) score for the highest PWM E-box
under each peak against the rank of the peaks dem-
onstrates that the average PWM for the low ranked
peaks (rank > 85,000) falls off more rapidly for the
Figure 3 MyoD has a similar E-box preference for both endogenous and overexpressed MyoD. (A) Overexpressed MyoD (lenti) and
endogenous MyoD (primary.tube) have similar E-box distributions. We collected all genomic E-boxes (excluding sex chromosomes and those
present in the peaks of the control samples) and ranked them based on p-values for the read coverage at the E-boxes. We partitioned them into
bins of top 1K, top 1001 to 10K, etc., until all E-boxes are included. Within each bin, we calculated the percentage of each type of E-box variant,
and plotted the distribution. The background E-box distribution over the entire genome is also included as a reference. (B) MYOD binding sites
for overexpressed MyoD (lenti) and endogenous MyoD (primary.tube) share the same sequence preference. We used motif discovery to identify
the E-box motif under MyoD bound peaks for the top 35K, the top 35K+1 to 70K peaks, and the top 70K+1 to 110K peaks. The E-box sequence
preferences are nearly identical, including within the flanking regions. Motifs in lower ranking peaks tend to have slightly more sequence
degeneracy. (C) MyoD E-box average PWM score compared to peak rank. The MyoD PWM is derived from our previous study [4]. Weak peaks
tend to have weaker motifs, but the degradation is more gradual for overexpressed MyoD peaks (lenti) beyond the top 67K, suggesting that a
subset of noisy low peaks in the endogenous MyoD (primary.tube) is elevated to reasonably strong peaks distinguished from the
background. X-axis: the peak rank bins. Y-axis: the average PWM scores for all peaks within the rank bin.
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(Figure 3C). This likely reflects the difficulty of accur-
ately discriminating weak MyoD binding sites from
background reads for the endogenous MyoD, whereas
the lenti-MyoD maintains a higher average E-boxPWM score, suggesting that the overexpression of
MyoD enhances the ability to discriminate weaker
MyoD binding sites from background. Taken together,
the data indicate that overexpressed MyoD in MEFs
binds to a nearly identical set of sites and E-boxes as
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a substantial number of off-target sites.
To determine whether overexpressed MyoD was bound
to all of the E-boxes that match the consensus site, we
graphed the number of reads over all the RRCAGSTG
sites in the mappable genome (Figure 4A), sub-sampling
the same number of reads for both the overexpressed
and endogenous MyoD ChIP-seq data sets. Despite
overexpression in the lenti-MyoD samples, the majority
of these high PWM E-boxes had one read or less, similar
to the endogenous-MyoD samples, and for both samples
fewer than 25% of these high PWM E-boxes had more
than four reads. Therefore, for both the endogenous and
overexpressed MyoD, a minor subset of high PWM
E-boxes was occupied by MyoD.
Previously, we had measured E-box accessibility in
fibroblasts prior to the expression of MyoD by exposing
isolated nuclei to the restriction enzyme PvuII, which
cleaves at CAGCTG E-boxes [4]. Using these data, we
assigned each CAGCTG E-box to one of three groups:
relatively inaccessible, moderately accessible, or highly
accessible. About 40% of all highly accessible CAGCTG
E-boxes had more than four reads in the endogenous
MyoD samples, and slightly over 50% had four or more
reads in the overexpressed MyoD samples; this compares
to approximately 15% for both samples over the rela-
tively inaccessible E-boxes (Figure 4B). However, only
about one-third of the highly accessible group had read
coverage above the average cutoff for the top ~70,000
peaks (11 reads for endogenous MyoD and 26 reads for
overexpressed MyoD). Therefore, E-box accessibility in
the chromatin was a major determinant of MyoD bind-
ing, but a large fraction of relatively highly accessible
E-boxes with a strong PWM remained unbound by
MyoD, indicating that only a subset of accessible E-boxes
with a good PWM showed substantial MyoD binding even
when MyoD was overexpressed. In this regard, our prior
study [4] showed that several sequence motifs were
enriched in the region of bound accessible sites (additional
E-boxes, higher PWM E-boxes, and a motif similar to a
MEIS binding site), indicating that several factors might
operate to enhance or stabilize MyoD binding at subsets
of accessible sites.
Co-factor motifs and MyoD binding
Although there was a very high concordance of binding
sites for endogenous MyoD in mouse muscle cells and
overexpressed MyoD in MEFs, there was some differ-
ence in peak rank, as evidenced by a 67% overlap of the
top 35,000 peaks in each set with most of the additional
33% of peaks present in the other set at lower rank.
Since the E-box motifs were similar in both sets and did
not apparently account for rank differences, we exam-
ined the top 30,000 peaks in each set for co-factor motifsusing a de novo motif search strategy (see Methods). The
peaks in the mouse muscle cells were enriched in E-box
motifs (>7-fold) and had modest enrichment for several
other motifs: MEIS (1.6-fold), RUNX (1.3-fold), and AP1
(2.2-fold). Similarly, the peaks in the MEFs with
overexpressed MyoD were enriched for E-box motifs
(>6-fold), MEIS (1.6-fold), and RUNX (1.4-fold) relative to
the background sequence (Additional file 1: Figure S2A). It
remains possible that some of the rank differences reflect
the relative abundance of co-factors in the different cell
backgrounds, but there is not a strong association of a spe-
cific factor motif with the MyoD binding sites.
Although there was about 90% concordance between
endogenous and overexpressed MyoD peaks, albeit with
some difference in ranking position, approximately 5-7%
of the highly ranked peaks in each set was not repre-
sented in the top 110,000 peaks in the other set. Motif
analysis of the sequences under the endogenous-only
peaks (i.e., ranked in the top 30,000 endogenous peaks
but not in the top 110,000 lenti-MyoD peaks) compared
to peaks only present in the lenti-MyoD (i.e., ranked in
the top 30,000 lenti-MyoD peaks but not in the top
110,000 endogenous MyoD peaks) showed an enrich-
ment of a variant of the RUNX motif (2-fold), a PITX-
like motif (4-fold), and a CGNCAG motif (2.7-fold). A
similar motif analysis comparing the endogenous-only
peaks to shared peaks also revealed the RUNX and
PITX-like motifs, albeit at a slightly lower fold enrich-
ment. The comparable analysis to identify motifs in the
lenti-only peaks revealed a slight enrichment for E-boxes
with non-preferred core sequences (Additional file 1:
Figure S2B), indicating that a small number of the lenti-
only peaks might represent binding to lower affinity
sites, possibly driven by the higher amount of MyoD.
Therefore, while there might be some contribution of
co-factors expressed in the mouse muscle cells that ac-
counts for the small number of endogenous-only peaks,
the motif analysis does not identify more than a modest
enrichment of the motif for any specific factor, consist-
ent with the finding that the MyoD binding sites in both
cells types show over 90% concordance.
Discussion
We conclude that overexpression of MyoD can accur-
ately identify endogenous MyoD binding sites. This is
true despite the fact that the binding pattern of the en-
dogenous MyoD was determined in skeletal muscle cells
(primary myotubes and differentiated C2C12 cells),
whereas the binding sites of the overexpressed MyoD
were determined in MEFs. The concordance of binding
sites in these two cell types might reflect the ability of
MyoD to convert MEFs to skeletal muscle. In this
process, MyoD activates the expression of many co-
factors that cooperate in a feed-forward circuit with
Figure 4 MyoD binds a subset of accessible E-boxes. (A) Coverage distribution over consensus MyoD binding sites RRCAGSTG. X-axis: log2
transformed coverage. Y-axis: the proportion of sites with coverage greater than the given value x. To make read coverage more comparable, we
sub-sampled the same number of reads in each group. The distributions of coverage at RRCAGSTG sites in both samples are shown in solid lines.
For comparison, E-boxes other than RRCAGSTG sites are shown in dashed lines. Only the E-boxes that are uniquely mapped within a ±200-bp
window are included. (B) Coverage distribution over E-boxes similar to panel A but divided into E-boxes showing relatively low accessibility (0,1],
moderate accessibility (1,2], or relatively high accessibility (2,Inf], as previously determined by PvuII accessibility [4].
Yao et al. Skeletal Muscle 2013, 3:8 Page 7 of 9
http://www.skeletalmusclejournal.com/content/3/1/8
Yao et al. Skeletal Muscle 2013, 3:8 Page 8 of 9
http://www.skeletalmusclejournal.com/content/3/1/8MyoD to orchestrate gene expression [7-9]. Since MyoD
can activate its own co-factors, the initial differences in
co-factor expression between muscle cells and MEFs
might not alter the ultimate binding pattern of MyoD.
In differentiating muscle cells, MyoD binds DNA as a
heterodimer with an E-protein. However, in vitro
binding studies demonstrate that MyoD can form
homodimers and bind E-boxes. Therefore, we had antic-
ipated that overexpressed MyoD might bind as a
homodimer because of limiting amounts of E-proteins.
Surprisingly, we do not think there is any evidence for
homodimer binding. The E-box motif analysis of the en-
dogenous MyoD has asymmetric flanking sequences:
RRCAGSTG. In a recent study we have shown that
NeuroD2 binds an E-box with similar flanking prefer-
ences on one side: RRCAGMTGG [4]. Because both
MyoD and NeuroD2 form heterodimers with the same
E-proteins, we assume that the flanking RR is deter-
mined by the common E-protein partner, and initial
binding studies support this conclusion (AP Fong, un-
published data). Since these flanking preferences are
maintained at the E-boxes when MyoD is overexpressed,
it suggests that the E-protein determined sequence pref-
erence is maintained and that MyoD is binding as a
heterodimer even when overexpressed. It is possible that
the requirement for heterodimer binding prevents off-
target DNA binding by the overexpressed MyoD since
the amount of the E-protein dimerization partner would
be limiting.
The fact that overexpression of MyoD improved the
foreground-to-background signal and permitted site deter-
mination at higher p-value stringency suggests that many
of the MyoD binding sites might not be occupied 100% of
the time at endogenous levels of MyoD, although this re-
mains speculative since other unknown variables might
have affected the ChIP efficiencies or foreground/back-
ground read ratios in the different experiments. With these
caveats in mind, if the majority of sites are not saturated by
physiological levels of MyoD (i.e., not bound by MyoD
100% of the time) then these would present a large “sink”
for the overexpressed MyoD protein, which might further
limit ectopic binding. In this regard, it is interesting to note
that re-analysis of published c-Myc binding ChIP-seq data
[6] under low and high serum conditions that result in an
approximately five-fold change in c-Myc mRNA also
shows enhanced binding of weakly bound sites with in-
creased c-Myc levels (ZY and SJT, unpublished data).
Furthermore, while this manuscript was under review, Lin
et al. [10] demonstrated that increased amounts of c-Myc
protein resulted in greater saturation of weakly bound c-
Myc sites near promoters and this was associated with
increased gene transcription. Additional studies will be
required to determine whether increased MyoD bind-
ing at physiologically unsaturated sites has a similarfunction in enhancing gene transcription. Together these
findings suggest that transcription factor overexpression,
e.g., induced by gene amplification or other mechanisms
in cancers, might have major biological consequences as a
result of increased binding at physiologically bound sites.Conclusions
Our comparison of genome-wide binding of endogenous
MyoD with overexpressed MyoD demonstrated that
overexpressed MyoD binds to the same sites as endo-
genous MyoD and does not demonstrate binding to novel
regions or motifs. The samples with overexpressed MyoD
showed better foreground-to-background signal and per-
mitted site determination at higher statistical significance,
suggesting that increased amounts of transcription factor
increased the binding at physiologically bound sites. Over-
all, our study shows that overexpression of MyoD accur-
ately identifies sites bound by endogenous MyoD and
demonstrates an intrinsic biological robustness for varying
levels of transcription factor in a cell.Accession numbers
ChIP-seq data have been deposited in Gene Expression
Omnibus (GEO) under accession number GSE34906 (lenti-
overepressed MyoD) and in DDBJ Sequence Read Archive
(DRA) accession number SRP001761 (endogenous MyoD).Additional file
Additional file 1: Figure S1. (A) The percentage of genome covered at a
given p-value significance. X-axis corresponds to the negative logarithm of the
p-value significance level, and Y-axis is the fraction of genome covered, both
in log10 scale. The pink curve (ref) corresponds to the estimated percentage
of genome covered at the given p-value cutoff based on the null hypothesis
in each sample, and the blue curve (obs) is the observed percentage of
genome covered at the given p-value cutoff. FDR is defined as the ratio of
observed vs. background genome covered at a given p-value. The three
panels correspond to overexpressed MyoD (lenti), endogenous MyoD
(primary.tube), and the control samples (control). (B) Pairwise comparison of
control samples. We have three types of control: pooled reads from pre-
immune ChIP in muscle cells (Tube preimmune), MyoD antisera ChIP in MEFs
that do not express MyoD (MEF control), and beads alone (MEF bead). Reads
from all control lanes are pooled to infer peaks at very low significance (p-
value 10-3), and we calculate the maximum coverage for each sample at
these peaks. The pairwise comparison of coverage of each sample in square
root transformation is shown. Figure S2: Motif enrichment analysis for
regions under overexpressed MyoD peaks and endogenous MyoD peaks. (A)
Motifs enriched under all overexpressed MyoD peaks (lenti) or all endogenous
MyoD peaks (primary.tube). (B) Motifs specific to endogenous or
overexpressed MyoD peaks. Primary-Lenti: Motifs enriched in peaks present
only in endogenous MyoD compared to peaks present only in overexpressed
MyoD. Primary-Shared: Motifs enriched in endogenous-only peaks compared
to peaks present in both groups, i.e., shared peaks. Lenti-Shared: Motifs
enriched in peaks only in overexpressed MyoD compared to shared peaks.
Consensus, consensus sequence for the motif; Anno, annotated factor for motif
consensus; scores, the regression z-values representing the discriminative
power of the motif for separating the foreground and background where
positive values indicate enriched motifs and negative values indicate depleted
motifs; ratio, the enrichment (or depletion) ratio of the motifs in the
foreground relative to the background; fg.frac, the percentage of the
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background sequences containing the motif; logo, the PWM logo.
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